Hadassah Completes Phase I Trial With Israeli-Made COVID-19 Vaccine

Tuesday, Dec 1 2020

Phase I of the first clinical trial with Brilife, the COVID-19 vaccine developed by the Israel Institute for Biological Research, was completed at Hadassah Hospital Ein Kerem on November 26, when the 40th participant received the final dose.

Participants ranged in age from 18 through 55 and did not have any pre-existing illnesses. They are being closely monitored by Hadassah staff through medical examinations, phone calls and a dedicated phone app, which they use to report their health status to Hadassah.

Hannah Drory, clinical study coordinator at Hadassah’s Center for Clinical Research, where the vaccine is being administered, reported that “communication with the participants has been excellent, and their cooperation has been wonderful.”

Prof. Yossi Karko, director of the center, explained the success to date: “From monitoring the participants who have been vaccinated so far, we see no unusual side effects, and this seems promising in terms of safety, which is the point of the first stage of the experiment. We can now look forward to the next stage.”

Phase I of the trial is also being conducted at Israel’s Sheba Medical Center. In the much larger Phase II trial, which will begin soon, Hadassah and Sheba plan to enroll individuals aged 18 through 85, including some people with pre-existing conditions.

“Ahead of my last birthday, I realized that all I wanted was to do some good in this world,” noted Hava Cohen Ayoubi, age 30, from the southern Hebron hills. “My fears dissipated as soon as I entered the center,” she said. “The staff was extremely professional and careful. I’m really pleased I did this.”

Hava added, “If you want to join the next stage of the trial, just get in touch with the center and do a little something for the world.”

Related Stories

alt_text

Tuesday, Jan 12 2021

Hadassah Speedily Vaccinates Its Staff Against COVID-19

As of January 11, out of the 6,500 individuals who work at the Hadassah Medical Organization, 4,800 had received their first dose of the Pfizer vaccine, and 1,000 had received the second dose.

READ MORE ›
alt_text

Tuesday, Jan 5 2021

Mary, From Bethlehem, Experiences Personal Christmas Miracle at Hadassah

Christmas Eve is always a special time for Mary A, an 86-year-old resident of Bethlehem.

READ MORE ›
alt_text

Tuesday, Dec 29 2020

Nurses Inject Hope at Hadassah Hospital Ein Kerem

The sun has just come up. It is 6 am and 18 pairs of eyes are staring at two Hadassah Hospital Ein Kerem nurses. One nurse is seated and the other is standing over her, a needle in hand.

READ MORE ›
alt_text

Monday, Dec 21 2020

What Are Organoids? Welcome to a Revolution in Basic Medical Science

Classically, researchers in basic medical science have had two tools: in vitro cultures and animal models. The challenges posed by their limitations are many.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

More ›

Show More